TransMedics Group Inc (TMDX) Q3 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...

GuruFocus.com10-29

Total Revenue: $108.8 million, representing 64% growth from Q3 2023. US Revenue: $104.9 million, a 76% increase from Q3 2023. Transplant Logistics Service Revenue: $20.1 million, up from $2.1 million ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479728203?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/xKc_Eps_fuc3tXC4LnqH1A--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/792f66dc2a566e38641ccc79a13d06f1","is_english":true,"pubTime":"2024-10-29 23:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2479728203","market":"us","top_or_hot":-1,"title":"TransMedics Group Inc (TMDX) Q3 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...","media":"GuruFocus.com","content":"<div>\n<p>Total Revenue: $108.8 million, representing 64% growth from Q3 2023.\nUS Revenue: $104.9 million, a 76% increase from Q3 2023.\nTransplant Logistics Service Revenue: $20.1 million, up from $2.1 million ...</p>\n\n<a href=\"https://finance.yahoo.com/news/transmedics-group-inc-tmdx-q3-150035967.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TransMedics Group Inc (TMDX) Q3 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTransMedics Group Inc (TMDX) Q3 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-29 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/transmedics-group-inc-tmdx-q3-150035967.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Total Revenue: $108.8 million, representing 64% growth from Q3 2023.\nUS Revenue: $104.9 million, a 76% increase from Q3 2023.\nTransplant Logistics Service Revenue: $20.1 million, up from $2.1 million ...</p>\n\n<a href=\"https://finance.yahoo.com/news/transmedics-group-inc-tmdx-q3-150035967.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TMDX","symbol_name":"TransMedics Group Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/transmedics-group-inc-tmdx-q3-150035967.html","article_id":"2479728203","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/xKc_Eps_fuc3tXC4LnqH1A--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/792f66dc2a566e38641ccc79a13d06f1"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479728203","pubTimestamp":1730214035,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Total Revenue: $108.8 million, representing 64% growth from Q3 2023.US Revenue: $104.9 million, a 76% increase from Q3 2023.Transplant Logistics Service Revenue: $20.1 million, up from $2.1 million in Q3 2023.Gross Margin: 56%, down from 61% in Q2 2024.GAAP Operating Profit: $3.9 million, representing 4% of total revenue.Cash Position: $330.1 million as of September 30, 2024.Annual Revenue Guidance: $425 million to $445 million, representing 76% to 84% growth over full year 2023.GuruFocus has detected 4 Warning Signs with TMDX.For the complete transcript of the earnings call, please refer to the full earnings call transcript.TransMedics Group Inc  achieved a GAAP operating profit of $3.9 million in Q3, representing 4% of total revenue.A: The $2 million of non-recurring expenses will not recur next quarter. We expect service margins to improve as we utilize our own","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TMDX":"TransMedics Group Inc."},"translate_title":"TransMedics Group Inc(TMDX)2024年第三季度收益看涨期权亮点：收入强劲增长...","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMDX":1},"content_text":"Total Revenue: $108.8 million, representing 64% growth from Q3 2023.\nUS Revenue: $104.9 million, a 76% increase from Q3 2023.\nTransplant Logistics Service Revenue: $20.1 million, up from $2.1 million in Q3 2023.\nGross Margin: 56%, down from 61% in Q2 2024.\nGAAP Operating Profit: $3.9 million, representing 4% of total revenue.\nNet Income: $4.2 million.\nCash Position: $330.1 million as of September 30, 2024.\nAnnual Revenue Guidance: $425 million to $445 million, representing 76% to 84% growth over full year 2023.\n\n\nWarning! GuruFocus has detected 4 Warning Signs with TMDX.\n\nRelease Date: October 28, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nTransMedics Group Inc (NASDAQ:TMDX) reported a 64% year-over-year revenue growth for Q3 2024, driven by a 76% increase in US sales.\nThe company has expanded its fleet to 18 owned aircraft, enhancing its logistics and aviation infrastructure.\nTransMedics Group Inc (NASDAQ:TMDX) is investing in next-generation OCS heart and lung technologies, with plans to launch new clinical programs in 2025.\nThe company maintained its annual revenue guidance range of $425 million to $445 million, representing 76% to 84% growth over 2023.\nTransMedics Group Inc (NASDAQ:TMDX) achieved a GAAP operating profit of $3.9 million in Q3, representing 4% of total revenue.\n\n Negative Points \n\nThe company experienced a 5% sequential decline in total revenue from Q2 2024, with US sales declining 3% and OUS sales declining 45%.\nGross margins decreased to 56% in Q3 from 61% in Q2 2024, due to continued investments in logistics and reliance on third-party logistics partners.\nTransMedics Group Inc (NASDAQ:TMDX) faced headwinds from a decline in US national transplant volumes, impacting case volumes.\nThe company incurred approximately $2 million in non-recurring costs related to logistics and infrastructure investments.\nThere was a higher reliance on third-party logistics partners due to aircraft maintenance, affecting service margins.\n\n Q & A Highlights \nQ: Can you provide insights into the dynamics observed in the fourth quarter and the confidence in reiterating the guidance? A: We have seen dynamics starting to normalize in early October, which gives us confidence in reiterating the guidance set for ourselves. - Waleed Hassanein, President, CEO\nQ: What caused the decline in heart transplants after a strong second quarter, and is there any competitive impact? A: There is no impact from competitive dynamics or technologies on the decline in Q3 heart transplants. The decline was due to a national volume decrease, and Transmedics continues to hold a significant share of DCD heart donations in the U.S. - Waleed Hassanein, President, CEO\nQ: How should we think about the service margin improvements and the impact of non-recurring expenses? A: The $2 million of non-recurring expenses will not recur next quarter. We expect service margins to improve as we utilize our own planes more and reduce reliance on third-party logistics. - Stephen Gordon, CFO\nQ: Can you elaborate on the impact of aircraft maintenance on operations and future expectations? A: We had more aircraft down for maintenance in Q3 than usual, impacting margins. We plan to manage maintenance better and have 18 planes, with plans to add a few more, aiming for operational efficiency. - Waleed Hassanein, President, CEO and Stephen Gordon, CFO\nQ: What are the expectations for the new OCS heart and lung technologies launching in 2025? A: The new technologies involve improved perfusion solutions and clinical use models, aiming to enhance transplant outcomes and enable multi-organ transplants. Clinical programs will demonstrate these advancements in 2025. - Waleed Hassanein, President, CEO\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479728203"}